December 16, 2016 - 7:39 pm
0 Comments

  The supply of almost every Schedule II opioid manufactured in the U.S. will be reduced 25% or more in 2017, as required by the Drug Enforcement Administration (DEA). DEA expects the new quota will be sufficient to meet